FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 

Has this patient's data been previously reported to USIDNET?

  
 nmlkji

yes  
 nmlkji

no  

 
 
USIDNET ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
specify    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 

Report the most recent findings since the date of the last report. For questions 1–3 and 6–7, also report CBC results in the Form 2100 – 100 Days Post-HSCT Data beginning at 
question 48, or in the Form 2200 — Six Months to Two Years Post-HSCT Data beginning at question 19. 

 
1  Date of most recent hematologic testing: __ __ __ __ - __ __- __ __  

  
 
2  WBC:    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

WBC not tested

  
 
3  Lymphocytes:    % 

 
  

gfedcb
Lymphocytes not tested

  
 
4  Eosinophils:    % 

 
  

gfedcb
Eosinophils not tested

  
 
5  Polymorphonuclear leukocytes (PMN):    % 

 
  

gfedcb
Polymorphonuclear leukocytes (PMN) not tested

  
 
6  Hemoglobin:    

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 
 

  
gfedcb

Hemoglobin not tested

 
 

  
gfedcb

transfused RBC < 30 days from date of most current testing

Key Fields 

  Laboratory Studies Post-HSCT Questions: 1 - 50

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 13



  
 
7  Platelets:    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

Platelets not tested

 
 

  
gfedcb

transfused platelets < 7 days from date of most current testing

  
 
8  Mean platelet volume:    fl 

 
  

gfedcb
Mean platelet volume not tested

 
 

9  What was the platelet size at the date of the most recent follow-up?

    
 nmlkji

Decreased  
 nmlkji

Normal  
 nmlkji

Unknown  

  

Immunoglobulin Analysis 

 
Specify the most recent quantitative immunoglobulins measured since the date of the last report. 

For questions 10–15, also report immunoglobulins in the Form 2100 – 100 Days Post-HSCT Data beginning at question 55, or in the Form 2200 — Six Months to Two Years Post-
HSCT Data beginning at question 26. 

For questions 18–19, also report IVIG in the Form 2100 – 100 Days Post-HSCT Data beginning at question 61, or in the Form 2200 — Six Months to Two Years Post-HSCT Data 
beginning at question 32. 

 
10  IgG:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

  
gfedcb

IgG not tested

 
 
11  Date tested: __ __ __ __ - __ __- __ __  

  
 
12  IgM:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

  
gfedcb

IgM not tested

 
 
13  Date tested: __ __ __ __ - __ __- __ __  

  
 
14  IgA:    

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

  
gfedcb

IgA not tested

 
 
15  Date tested: __ __ __ __ - __ __- __ __  

 
 
16  IgE:    IU/mL 

  
 
17  Date tested: __ __ __ __ - __ __- __ __  

 
  

gfedcb
IgE not tested

 
 

18  Did the recipient receive supplemental intravenous immunoglobulins (IVIG)(since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

19  Was therapy ongoing within one month of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Lymphocyte Analysis 

Specify the most recent lymphocyte assessment measured since the date of the last report. 

For questions 21 and 23–27, also report lymphocytes in the Form 2100 – 100 Days Post-HSCT Data beginning at question 71, or in the Form 2200 — Six Months to Two Years 
Post-HSCT Data beginning at question 42. 

 
20  Were lymphocyte analyses performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 
21  Date of most recent testing performed: __ __ __ __ - __ __- __ __  

 
 
22  Absolute lymphocyte count:    

cells / µL (cells / mm3)
 

 
 
23  CD3 (T cells) % of total lymphocytes    % 

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 13



  

- OR - 
 
CD3 (T cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD3 (T cells) not tested

 
 
24  CD4 (T helper cells) % of total lymphocytes    % 

  

- OR - 
 
CD4 (T helper cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4 (T helper cells) not tested

 
 
25  CD8 (cytotoxic T cells) % of total lymphocytes    % 

  

- OR - 
 
CD8 (cytotoxic T cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD8 (cytotoxic T cells) not tested

 
 
26  CD20 (B lymphocyte cells) % of total lymphocytes    % 

  

- OR - 
 
CD20 (B lymphocyte cells) value:    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD20 (B lymphocyte cells) not tested

 
 
27  CD56 (natural killer (NK) cells) % of total lymphocytes    % 

  

- OR - 
 
CD56 (natural killer (NK) cells) value    

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD56 (natural killer (NK) cells) not tested

 
 
28  CD4+/CD45RA+ (naive T cells) % of total lymphocytes    % 

  

- OR - 
 
CD4+/CD45RA+ (naive T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4+/CD45RA+ (memory T cells) not tested

 
 
29  CD4+/CD45RO+ (memory T cells) % of total lymphocytes    % 

  

- OR - 
 
CD4+/CD45RO+ (memory T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

CD4+/CD45RO+ (memory T cells) not tested

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 13



 

Antibody Response 

Specify the most recent antibody responses measured since the date of the last report. 

 
30  Date antibody responses were assessed: __ __ __ __ - __ __- __ __  

 
 

31  Bacteriophage phi X-174 or other neoantigen

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

32  Diptheria

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

33  Isohemagglutinin anti-A

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

34  Isohemagglutinin anti-B

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

35  Protein conjugated HIB or pneumococcal vaccine

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

36  Tetanus

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

  
 

37  Unconjugated pneumococcal polysaccharide:    / 

    
Number of serotypes producing a protective level / Total serotypes tested from vaccine 

 

 
.    

  
 

38  Conjugated pneumococcal polysaccharide:    / 

    Number of serotypes producing a protective level / Total serotypes tested from vaccine 

 
.    

 

Lymphocyte Function 
Specify the most recent lymphocyte function measured since the date of the last report 

 
39  Date lymphocyte function was assessed: __ __ __ __ - __ __- __ __  

 
 

40  Anti-CD3

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

41  Candida antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

42  Concavalin A (ConA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 13



 
 

43  Phytohemagglutinin (PHA)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

44  Pokeweed mitogen (PWM)

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

45  Tetanus antigen

    
 nmlkji

Absent  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal  

 nmlkji
Not tested  

 
 

46  What is the current natural killer cell function? (Refers to specific cytolysis of NK-sensitive target cells, e.g. K562.)

    
 nmlkji

absent (<= 10% normal response)  

 nmlkji
decreased(11-50% normal response)  

 nmlkji
Normal  

 nmlkji
Unknown  

 
 

47  Did a new malignancy, lymphoproliferative or myeloproliferative disorder appear that is different from the disease for which the HSCT was performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Specify second malignancy:

    
 nmlkji

EBV-associated B-cell lymphoproliferative disorder  

 nmlkji
other second malignancy  

 nmlkji
Unknown  

 
 
49  Specify other second malignancy:    

 
 
50  Specify the date of diagnosis: __ __ __ __ - __ __- __ __  

 

                Also report malignancy in the Form 2100 – 100 Days Post-HSCT Data beginning at question 519, Form 2200 — Six Months to Two Years Post-
HSCT Data beginning at question 459, or Form 2300 — Yearly Follow-Up for Greater Than Two Years Post-HSCT Data beginning at question 131. Copy 
questions 47–50 to report more than one secondary malignancy;   

 
  

gfedcb
Check here if additional pages are attached.

 
 

51  Did the recipient experience any types of bleeding (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

  New Malignancy (1) Questions: 48 - 50 

  Clinical Status of Recipient Post-HSCT Questions: 51 - 105

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 13



 

Specify types of bleeding: 

 
52  Is epistaxis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  Is epistaxis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

54  Is upper GI hemorrhage present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  Is upper GI hemorrhage prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Lower GI hemorrhage / rectal bleeding

    
 nmlkji

yes  
 nmlkji

no  

 
 

57  Is lower GI hemorrhage/rectal bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  Is hemarthrosis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

59  Is hemarthrosis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  Is hematuria present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

61  Is hematuria prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  Is intracranial hemorrhage present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  Is intracranial hemorrhage prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Is oral bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  Is oral bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

66  Is subcutaneous bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

67  Is subcutaneous bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  Is subdural hematoma present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

69  Is subdural hematoma prominent?

    
 nmlkji

yes  
 nmlkji

no  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 13



 
 

70  Is other bleeding present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  Is other bleeding prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
72  Specify other bleeding:    

 
 

73  Did the recipient experience any autoimmune / inflammatory disorders (since the date of the last report?)

    
 nmlkji

yes  
 nmlkji

no  

 

Specify autoimmune / inflammatory disorders: 

 
74  Is arthralgia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

75  Is arthralgia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  Is chronic arthritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Is chronic arthritis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Is autoimmune hemolytic anemia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Is autoimmune hemolytic anemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Is idiopathic thrombocytopenic purpura (ITP) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Is idiopathic thrombocytopenic purpura (ITP) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Is inflammatory bowel disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  Is inflammatory bowel disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  Is juvenile rheumatoid arthritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  Is juvenile rheumatoid arthritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Is nephritis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Is nephritis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Is neutropenia present?

    
 nmlkji

yes  
 nmlkji

no  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 13



 
 

89  Is neutropenia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  Is sclerosing cholangitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  Is sclerosing cholangitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Is cerebral vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Is cerebral vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Is coronary vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

95  Is coronary vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

96  Is renal vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

97  Is renal vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

98  Is skin vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

99  Is skin vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Is other vasculitis present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  Is other vasculitis prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
102  Specify other vasculitis:    

 
 

103  Is any other disorder present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Is any other disorder prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
105  Specify other disorder:    

 
 

106  Was any treatment given for relapsed, persistent, or progressive disease (since the date of the report)?

    
 nmlkji

yes  
 nmlkji

no  

  Post-HSCT Treatment for Wiskott-Aldrich Syndrome Questions: 106 - 168

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 13



 

Also report immunosuppressive medications given to prevent or treat GVHD in the corresponding questions on the Form 2000 — Recipient Baseline Data, Form 
2100 — 100 Days Post-HSCT Data, Form 2200 — Six Months to Two Years Post- HSCT Data, or Form 2300 — Yearly Follow-Up for Greater Than Two Years Post-
HSCT Data. 

Therapy paused for < 1 week should not be considered as “Therapy Stopped.” 
 

107  Antithymocyte globulin (ATG, ATGAM, Thymoglobulin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Was therapeutic antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
109  Date therapeutic antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

110  Were systemic corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  Were therapeutic systemic corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
112  Date therapeutic systemic corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

113  Were topical corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Were therapeutic topical corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
115  Date therapeutic topical corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

116  Was cyclophosphamide (CTX, Cytoxan, Neosar) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

117  Was therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
118  Date therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

119  Was cyclosporine (CsA, Neoral, Sandimmune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

120  Was therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
121  Date therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped? __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

122  Was in vivo monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 13



 

Specify monoclonal antibody: 

 
123  Was alemtuzumab (Campath) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

124  Was therapeutic alemtuzumab (Campath) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
125  Date therapeutic alemtuzumab (Campath) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

126  Was daclizumab (anti-CD25, Zenapax) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

127  Was therapeutic daclizumab (anti-CD25, Zenapax) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
128  Date therapeutic daclizumab (anti-CD25, Zenapax) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

129  Was etanercept (Enbrel) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

130  Was therapeutic etanercept (Enbrel) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
131  Date therapeutic etanercept (Enbrel) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date 

unknown  

 
 

132  Was infliximab (anti-TNF-α, Remicade) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

133  Was therapeutic infliximab (anti-TNF-α, Remicade) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
134  Date therapeutic infliximab (anti-TNF-α, Remicade) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

135  Was muromonab (anti-CD3, OKT3) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

136  Was therapeutic muromonab (anti-CD3, OKT3) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
137  Date therapeutic muromonab (anti-CD3, OKT3) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

138  Rituximab (anti-CD20, Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  

 
 

139  Was therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped?

    
 nmlkji

yes  
 nmlkji

no  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 13



  
 
140  Date therapeutic rituximab (anti-CD20, Rituxan, Mab Thera) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

141  Was any other monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

142  Was therapeutic other monoclonal antibody stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
143  Date therapeutic other monoclonal antibody stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
144  Specify other monoclonal antibody:    

 
 

145  Was lenalidomide (Revlimid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

146  Was therapeutic lenalidomide (Revlimid) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
147  Date therapeutic lenalidomide (Revlimid) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

148  Was mycophenolate mofetil (MMF, Cellcept) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

149  Was therapeutic mycophenolate mofetil (MMF, Cellcept) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
150  Date therapeutic mycophenolate mofetil (MMF, Cellcept) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date 

unknown  

 
 

151  Was photopheresis / extracorporeal phototherapy (ECP)given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

152  Was therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
153  Date therapeutic photopheresis / extracorporeal phototherapy (ECP) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date 

unknown  

 
 

154  Was sirolimus (Rapamune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

155  Was therapeutic sirolimus (Rapamune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
156  Date therapeutic sirolimus (Rapamune) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

157  Was tacrolimus (FK506, Prograf) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

158  Was therapeutic tacrolimus (FK506, Prograf) stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
159  Date therapeutic tacrolimus (FK506, Prograf) stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 13



 
 

160  Was thalidomide (Thalomid) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

161  Was therapeutic thalidomide (Thalomid)stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
162  Date therapeutic thalidomide (Thalomid)stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 

163  Was any other immunosuppressive drug given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

164  Was the other therapeutic immunosuppressive drug stopped?

    
 nmlkji

yes  
 nmlkji

no  

  
 
165  Date other therapeutic immunosuppressive drug stopped: __ __ __ __ - __ __- __ __  

 
.

 nmlkji
date estimated  

 nmlkji
Date unknown  

 
 
166  Specify other immunosuppressive drug:    

 
 

167  Did the recipient receive any other significant treatment(s) for WAS (since the date of the last report)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
168  Specify other treatment(s):    

 

This section refers to quantitative analyses utilizing discriminating DNA markers. Peripheral blood cells must undergo separation or sorting into T, B, or lymphoid vs. myeloid 

populations to perform this determination. If RFLP analyses indicate only donor type hematopoiesis, mark T-cell, B-cell, and myeloid as “predominantly or completely donor.” 

Also report chimerism in the Form 2100 – 100 Days Post-HSCT Data beginning at question 77 or Form 2200 — Six Months to Two Years Post-HSCT Data beginning at question 
48. 

 
169  What is the current status of T-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host T-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
170  Most recent date T-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent T-cell engraftment assessment unknown

 
 

171  What is the current status of B-cell engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host B-cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
172  Most recent date B-cell engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent B-cell engraftment assessment unknown?

 
 

173  What is the current status of myeloid engraftment?

    
 nmlkji

predominantly or completely donor (>= 80% donor chimerism)  

 nmlkji
Mixed chimerism  

 nmlkji
only host myeloid cells detected (< 5% donor)  

 nmlkji
Unknown  

  
 
174  Most recent date myeloid engraftment was assessed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of most recent myeloid engraftment assessment unknown

  Status of Hematologic Engraftment Questions: 169 - 174

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 13



  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2133 R3.0: Wiskott-Aldrich Syndrome Post-HSCT Data  
Center:  CRID: 

              CIBMTR Form 2133 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 13 / 13